The Quebec Cancer Foundation is proud to have participated on the advisory committee of the Institut National d’Excellence en Santé et Services Sociaux (INESSS) in the context of its examination of the suitability of Tisagenlecleucel (Kymirah) CAR-T cell therapy for Quebecers suffering from ALL-B or DLBCL r/r.
 
Through its Director General, Marco Décelles, the Foundation participated in this panel in the capacity of advisory member to representatives of associations interested in the issue. The aim of the committee was to ensure that a range of perspectives were taken into account and that the recommendations were appropriate to the Quebec context.
 
In so doing, the Foundation reaffirms its role as a social actor committed to the healthcare network and the various stakeholders in Quebec concerned with cancer.

On January 15, following the authorization granted to the Tisagenlecleucel (Kymirah) CAR-T cell therapy by INESSS, the Minister of Health and Social Services, Mrs. Danielle McCann, announced that children and young adults (aged 3–25) with acute lymphoblastic leukemia (ALL) who do not respond to standard treatments and who relapse after receiving a bone marrow transplant will soon be able to take advantage of this new therapy developed by the company Novartis.

"The addition of CAR T-cell therapy is an important new addition to the treatments available to people with cancer and Quebec is playing a leading role in developing this mode of treatment,” added Health and Social Services Minister Danielle McCann.

Comment on this article

Sign up for our newsletter

(In French only)